Cell and Gene Therapy

COVID-19 Vaccines Production and Analytical Chemistry Solutions

February 2, 2022

COVID-19 Vaccines
Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

Spotlight

Tango Therapeutics

Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.

OTHER WHITEPAPERS
news image

Impurity profiling and analysis of TheraPure GMP nucleotides

whitePaper | March 22, 2023

Nucleoside triphosphates (NTPs) are key building blocks of many nucleic acid therapeutics and vaccines. These molecules are a vital component of revolutionary new medicines.

Read More
news image

Accelerating the Biomanufacturing Revolution

whitePaper | February 11, 2022

The biomanufacturing revolution is here. Recent advancements in the field of synthetic biology have enabled significant cost reductions in foundational bioengineering unit operations such as DNA synthesis and sequencing.

Read More
news image

Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets

whitePaper | March 9, 2023

For biopharmaceutical and biotechnology companies, innovation is imperative. Economic growth in these industries relies heavily upon investment in product development—perhaps more so than any other industry

Read More
news image

70 years of wood modifcation with fungi

whitePaper | March 18, 2022

Fungi are usually seen by the wood used only as destroyers or parasites. Material infestation should be avoided as far as possible for wood preservation reasons.

Read More
news image

Challenges and Solutions for Gene Therapy manufacturing

whitePaper | November 17, 2022

Gene therapy is the modification of specific genes in targeted cells in order to address genetic mutations that cause some of the most debilitating human conditions.

Read More
news image

2022 Biosimilars Report: The U.S. Journey and Path Ahead

whitePaper | June 8, 2022

Cardinal Health is fortunate to sit at the crossroads of the United States (U.S.) healthcare system, engaging with stakeholders from across the industry including healthcare

Read More

Spotlight

Tango Therapeutics

Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.

Events